JP2003512304A - 医薬組成物および分泌フリズル化関連タンパクを用いる方法 - Google Patents

医薬組成物および分泌フリズル化関連タンパクを用いる方法

Info

Publication number
JP2003512304A
JP2003512304A JP2001523632A JP2001523632A JP2003512304A JP 2003512304 A JP2003512304 A JP 2003512304A JP 2001523632 A JP2001523632 A JP 2001523632A JP 2001523632 A JP2001523632 A JP 2001523632A JP 2003512304 A JP2003512304 A JP 2003512304A
Authority
JP
Japan
Prior art keywords
sfrp
hob
cells
bone
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001523632A
Other languages
English (en)
Japanese (ja)
Inventor
ピーター・ブイ・エヌ・ボディン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of JP2003512304A publication Critical patent/JP2003512304A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Husbandry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2001523632A 1999-09-13 2000-09-13 医薬組成物および分泌フリズル化関連タンパクを用いる方法 Pending JP2003512304A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39483299A 1999-09-13 1999-09-13
US09/394,832 1999-09-13
PCT/US2000/025035 WO2001019855A2 (en) 1999-09-13 2000-09-13 Pharmaceutical compositions and methods of using secreted frizzled related protein

Publications (1)

Publication Number Publication Date
JP2003512304A true JP2003512304A (ja) 2003-04-02

Family

ID=23560597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001523632A Pending JP2003512304A (ja) 1999-09-13 2000-09-13 医薬組成物および分泌フリズル化関連タンパクを用いる方法

Country Status (11)

Country Link
EP (1) EP1212355A2 (de)
JP (1) JP2003512304A (de)
CN (2) CN1387537A (de)
AU (1) AU7131200A (de)
BR (1) BR0014183A (de)
CA (1) CA2383360A1 (de)
CZ (1) CZ2002903A3 (de)
IL (1) IL148421A0 (de)
MX (1) MXPA02002624A (de)
NZ (1) NZ529560A (de)
WO (1) WO2001019855A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1196797C (zh) 2000-02-29 2005-04-13 阿尔康公司 青光眼的诊断和治疗药物
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
AU2001280680A1 (en) * 2000-07-19 2002-01-30 Genzyme Corporation Phosphatonin-related gene and methods of use thereof
US7488710B2 (en) 2001-01-10 2009-02-10 The United States Of America As Represented By The Department Of Health And Human Services SFRP and peptide motifs that interact with SFRP and methods of their use
EP1222933A1 (de) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Bildung und/oder Reduktion von neuem Lungengewebe in einer erkranketen Lunge, durch Modulierung des Wnt-Signalwegs
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US7682607B2 (en) 2001-05-01 2010-03-23 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
GB0111004D0 (en) * 2001-05-04 2001-06-27 Univ Sheffield Screening method
WO2003042384A1 (fr) * 2001-11-15 2003-05-22 Kyowa Hakko Kogyo Co., Ltd. Inducteur de differentiation pour cellules souches d'embryon, procede d'obtention dudit inducteur et utilisation
AU2003302926A1 (en) * 2002-12-05 2004-06-30 The Board Of Trustees Of The University Of Arkansas System Molecular determinants of myeloma bone disease and uses thereof
EP1616026A1 (de) * 2003-04-14 2006-01-18 Novartis AG Genexpression in der osteoblastichen differenzierung
CN104726460A (zh) * 2013-12-22 2015-06-24 上海交通大学医学院 蛋白sFRP-5在治疗银屑病的药物中的应用
EP3187191B1 (de) * 2014-08-26 2020-04-08 NKMAX Co., Ltd. Antikörper zur erkennung eines spezifischen motivs eines wls-proteins und pharmazeutische zusammensetzung damit
EP3696192A1 (de) * 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutisches target und monoklonale antikörper dagegen zur diagnose und behandlung von morbus alzheimer
CN110361541A (zh) * 2019-07-23 2019-10-22 上海交通大学医学院附属瑞金医院 sFRP2和PCPE1作为联合靶点在制备纤维化疾病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016641A1 (en) * 1996-10-11 1998-04-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Isolation and method of using tissue growth-inducing frzb protein
WO1998054325A1 (en) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Human frp and fragments thereof including methods for using them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681701A (en) * 1993-07-12 1997-10-28 Mayo Foundation For Medical Education And Research Immortalized human fetal osteoblastic cells
EP0769015B1 (de) * 1994-07-04 2001-03-14 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016641A1 (en) * 1996-10-11 1998-04-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Isolation and method of using tissue growth-inducing frzb protein
WO1998054325A1 (en) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Human frp and fragments thereof including methods for using them

Also Published As

Publication number Publication date
WO2001019855A2 (en) 2001-03-22
MXPA02002624A (es) 2002-07-30
BR0014183A (pt) 2002-05-14
EP1212355A2 (de) 2002-06-12
CN102988957A (zh) 2013-03-27
NZ529560A (en) 2005-05-27
CA2383360A1 (en) 2001-03-22
CZ2002903A3 (cs) 2002-07-17
WO2001019855A3 (en) 2002-01-24
CN1387537A (zh) 2002-12-25
AU7131200A (en) 2001-04-17
IL148421A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
JP2003512304A (ja) 医薬組成物および分泌フリズル化関連タンパクを用いる方法
JP2004524824A (ja) 機械的ストレスと関連する遺伝子、それらからの発現生成物、及びそれらの用途
JP2003508088A (ja) ５２個のヒト分泌タンパク質
KR20050090420A (ko) 메타스틴 유도체 및 이의 용도
JP2002535956A (ja) 物理的ストレスにより誘発される遺伝子、その発現産物およびその使用方法
JP2009213490A (ja) 骨及び／又は関節疾患関連遺伝子
JPH10509873A (ja) 治療薬
US20090226463A1 (en) Novel method of modulating bone-related activity
KR100553300B1 (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
JP2002112772A (ja) 新規ポリペプチドおよびそのｄｎａ
US20110020348A1 (en) Pharmaceutical compositions and methods using secreted frizzled related protein
JP2002525081A (ja) 低酸素により調節される遺伝子転写に特徴的な配列
JP2000217576A (ja) 脂肪細胞への分化を誘導する方法、並びに脂肪細胞への分化を制御する化合物およびそのスクリーニング方法
WO2000029441A1 (fr) Nouvelle proteine receptrice couplee a la proteine g, son adn et son ligand
EA007611B1 (ru) Белок, имеющий в своей структуре цистиновые узлы
EP1191096B1 (de) Neues protein und dessen dns
US7098372B1 (en) Pharmaceutical compositions and methods of using secreted frizzled related protein
JP2002530058A (ja) ３１個のヒト分泌タンパク質
AU2005201918B2 (en) Pharmaceutical compositions and methods of using secreted frizzled related protein
JP2002527104A (ja) Ｔｎｆｒ関連遺伝子１２
JP2003527831A (ja) エンドゼピン様ポリペプチドおよびエンドゼピン様ポリペプチドをコードするポリヌクレオチド
US7160720B2 (en) CHAMP—a novel cardiac helicase-like factor
JP2001505420A (ja) 肝臓アクチビン／インヒビンのヌクレオチド配列およびタンパク質配列ならびにそれらに基づく方法
JP2006525031A (ja) Ａｃｈｅｒｏｎ発現の制御方法
EP0933424A1 (de) Proteine c16 und c16n oder die dafür kodierenden gene.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018